Table 10 List of resources to be considered in the economic analysis Number of Disaggregated unit cost units of Proportion resource per Setting in which Provider of of patients relevant Other Private resource is Safety resource receiving time horizon MBS government health Patient Total cost provided nets* resource per patient budget insurer receiving resource Resources provided to identify eligible population To be To be Equivalent to current practice provided in provided in submission submission Resources provided to deliver proposed intervention (PD-L1 IHC test and pembrolizumab) PD-L1 IHC testing MBS Pathology lab To be To be provided in provided in submission submission To be To be Additional biopsy (if required) MBS Public or private provided in provided in hospital submission submission Resources provided in association with proposed intervention Pembrolizumab for patients PBS Outpatient To be To be provided in provided in deemed eligible based on PBS submission submission criteria To be To be Administration cost for Hospitals/MBS Inpatient/outpatient provided in provided in pembrolizumab and public and submission submission private hospitals To be To be Physician visits (Oncologist or MBS Outpatient provided in provided in respiratory physician) submission submission Clinical monitoring (radiological or MBS Outpatient To be To be provided in provided in other imaging, blood counts) submission submission Treatment of adverse events PBS Outpatient To be To be provided in provided in submission submission
Table 10 List of resources to be considered in the economic analysis Provider of resource Setting in which resource is provided Proportion of patients receiving resource Number of units of resource per relevant time horizon per patient receiving resource Disaggregated unit cost MBS Safety nets* Other government budget Private health insurer Patient Total cost Resources provided to identify eligible population Equivalent to current practice To be provided in submission To be provided in submission Resources provided to deliver proposed intervention (PD-L1 IHC test and pembrolizumab) PD-L1 IHC testing MBS Pathology lab To be provided in submission To be provided in submission Additional biopsy (if required) MBS Public or private hospital To be provided in submission To be provided in submission Resources provided in association with proposed intervention Pembrolizumab for patients deemed eligible based on PBS criteria PBS Outpatient To be provided in submission To be provided in submission Administration cost for pembrolizumab Hospitals/MBS Inpatient/outpatient and public and private hospitals To be provided in submission To be provided in submission Physician visits (Oncologist or respiratory physician) MBS Outpatient To be provided in submission To be provided in submission Clinical monitoring (radiological or other imaging, blood counts) MBS Outpatient To be provided in submission To be provided in submission Treatment of adverse events PBS Outpatient To be provided in submission To be provided in submission
1440%20-%20Final%20Protocol.docx